This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Beta-Ala-His dipeptidase.
Human | |
---|---|
Gene Name: | CNDP1 |
Uniprot: | Q96KN2 |
Entrez: | 84735 |
Belongs to: |
---|
peptidase M20A family |
beta-Ala-His dipeptidase; Carnosinase 1; carnosine dipeptidase 1 (metallopeptidase M20 family); Carnosine Dipeptidase 1; CN1MGC102737; CNDP dipeptidase 1; CNDP1; CPGL2; CPGL2MGC142072; EC 3.4.13.20; Glutamate carboxypeptidase-like protein 2; HsT2308; MGC10825; Serum carnosinase
Mass (kDA):
56.706 kDA
Human | |
---|---|
Location: | 18q22.3 |
Sequence: | 18; NC_000018.10 (74534500..74587212) |
Found in serum and adult nervous central system. Absent in serum from patients with homocarnosinosis.
Secreted.
There are many uses for the CNDP1 indicator. These include diagnostic, indicative, as well as combined. We will now discuss the CNDP1 marker's uses in more detail. We will also discuss the implications and use of the CNDP1 marker for diagnostic purposes. Here's how this marker can help your laboratory. You may be familiar with CNDP1, but you may not know all the uses it has in biomedicine.
The CNDP1 polymorphism is known as the 5-5 Leucine Repeat Allele. This allele is associated with a significantly lower risk of developing diabetes nephropathy. The susceptibility of DN may also be affected by the carnosine pathway. It is not known if CNDP1 markers can be used to diagnose. In this article we will discuss the possible uses of these markers in diagnosing and prognosis.
A genetic test of CNDP1 reveals the coding sequence includes four alleles that have a leucine repetition. This allele has a low level of linkage disequilibrium relative to the nearest polymorphic Exon. These findings have significant implications. The CNDP1 gene plays a significant role on chromosomes encoding Leucine. These findings are important because they are found in all types of cells, even those of cancer patients.
One embodiment of this disclosure includes CNDP1 marker to diagnose cancer. These markers were cloned using the pCS2 vector system, and then evaluated for differential expression by Cos-7 cells. The AUC values for the CNDP1 variants were significantly lower among men than in women, according to the authors. The researchers also found a statistically significant variation in carnosine levels among cancer patients with this mutation as well as patients who were treated with the same mutation.
In the study, marker candidates were selected from 60 normal people and sixty patients with liver cancer. Twenty-five samples from patients with hepatic and hepatocellular cancer were collected. 50 patients were cured of their disease and their cancer was gone. The markers are often more sensitive or specific than standard tests. They also improve the accuracy and speed of diagnosing liver cancer. They may also be used in biomarkers.
Two genes encode the CNDP1 or CNDP2 markers. CNDP1 encodes a dipeptidase which hydrolyzes the substrate l–carnosine. Carnosine plays a protective function in diabetic nephropathy. It is an antioxidant that can prevent the formation AGEs. These genes are linked with diabetes and diabetic kidney disease.
The effect CNDP1 has on diabetic nephropathy seems to be sex-specific. Women are only protected by the 5-5 heterozygous genotype. Three independent studies comparing the frequency of this genotype in type 2 diabetes patients with their general population counterparts revealed that it was significantly lower than in women. Researchers found that women had significantly lower frequency of the 5-5 homozygous variant. However, the 5-5 homozygous genotype had no protective effect on men.
PMID: 16046297 by Janssen B., et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1.
PMID: 7116644 by Lenney J.F., et al. Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium.